anti-ley-scfv-cd28-zeta vector
Cell therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2010 (NCT01716364)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- T-cell-specific surface glycoprotein CD28Immunity, passive
CD28 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-ley-scfv-cd28-zeta vector
- anti-ley-scfv-cd28-ζ vector
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01716364 | Phase 1 | Jan 1, 2010 | Peter MacCallum Cancer Centre |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Peter MacCallum Cancer Centre | Academic/Hospital | 1 | 1 | 1 | 2010 |
1 organizations
Page 1 / 1